Buy EUGIA-PAZOPANIB 200 MG PAZOPANIB (PAZOPANIB HYDROCHLORIDE

Eugia-Pazopanib 200 mg is an oral tablet containing pazopanib hydrochloride, used for targeted therapy. This medication is commonly prescribed for certain types of cancer, offering a convenient treatment option.

Strength

200 MG

Manufacturer / TM Owner

EUGIA PHARMA INC.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Eugia-Pazopanib 200 mg is primarily used in the treatment of advanced renal cell carcinoma and certain types of soft tissue sarcomas. Pazopanib, the active ingredient, works by inhibiting specific proteins that can contribute to cancer growth. Patients often wonder, 'What is pazopanib used for?' and the answer lies in its role as a targeted therapy for these specific cancer types.

Side Effects

Common effects of Eugia-Pazopanib 200 mg may include fatigue, nausea, and high blood pressure. Some users also report diarrhea and changes in hair color. These effects can vary widely among individuals, and it's important to discuss any concerns with a healthcare provider.

Precautions & Warnings

Eugia-Pazopanib 200 mg should be handled with care, especially regarding potential interactions with other medications. It is crucial to follow the advice of a healthcare professional regarding its use. Pregnant women and individuals with certain medical conditions should exercise caution.

Avoid Interactions

Eugia-Pazopanib 200 mg may interact with other medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain foods may also affect how this medication works.

References

Frequently Asked Questions

Eugia-Pazopanib 200 mg is used in the treatment of advanced renal cell carcinoma and certain types of soft tissue sarcomas.

Eugia-Pazopanib 200 mg is an oral tablet that should be taken as directed by a healthcare provider.

Common side effects may include fatigue, nausea, high blood pressure, diarrhea, and changes in hair color.

Eugia-Pazopanib 200 mg may interact with other medications, so it's important to consult a healthcare provider before combining it with other treatments.

Pregnant women should exercise caution when considering Eugia-Pazopanib 200 mg and consult a healthcare provider for personalized advice.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.